Form 8-K - Current report:
SEC Accession No. 0001171843-24-006945
Filing Date
2024-12-13
Accepted
2024-12-13 16:40:34
Documents
15
Period of Report
2024-12-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_121324.htm   iXBRL 8-K 15122
2 PRESS RELEASE exh_991.htm EX-99.1 46379
  Complete submission text file 0001171843-24-006945.txt   265256

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
18 EXTRACTED XBRL INSTANCE DOCUMENT f8k_121324_htm.xml XML 3157
Mailing Address 100 SPY COURT MARKHAM A6 L3R 5H6
Business Address 100 SPY COURT MARKHAM A6 L3R 5H6 (905) 475-1234
Edesa Biotech, Inc. (Filer) CIK: 0001540159 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37619 | Film No.: 241548979
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)